Endo International will spend about $8.05 billion to acquire Par Pharmaceutical as it expands its footprint in the generic drug market.
The deal includes about 18 million shares of Endo stock and $6.5 billion in cash, along with the assumption of debt. Par, based in Chestnut Ridge, New York, is owned by the private equity firm TPG. The deal is expected to close in the second half of 2015.
Continue Reading Below
Endo, based in Dublin, said it expects its generic drug unit to see double-digit revenue growth with the addition Par's portfolio of products.